Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy.
Cutaneous metastases from renal cell carcinoma (RCC) are uncommon, but may be painful and deforming. A review of the English language literature yields no references regarding the use of radiotherapy in the palliation of cutaneous RCC metastases. We report the first documented case of a patient with a single RCC facial metastatic nodule treated with hypofractionated electron beam radiotherapy followed by administration of sorafenib. The patient achieved a complete resolution of the cutaneous metastasis.
Gay
Hiram A
HA
Department of Radiation Oncology, The Brody School of Medicine at East Carolina University, Greenville, NC, USA.
Cavalieri
Ronaldo
R
Allison
Ron R
RR
Finley
James
J
Quan
Walter D
WD
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000532:radiotherapy* / Q000556:secondary; D005153:Facial Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000556:secondary; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010166:Palliative Care; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000556:secondary; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007376:Interleukin-2; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib